Unknown

Dataset Information

0

Chemotherapy-induced peripheral neuropathy in the detroit research on cancer survivors (ROCS) cohort.


ABSTRACT:

Purpose

Improved life expectancy has increased the likelihood for long-term complications from chemotherapy among cancer survivors. One burdensome complication is chemotherapy-induced peripheral neuropathy (CIPN). We evaluated rates of CIPN outcomes in the Detroit Research on Cancer Survivorship (ROCS) cohort.

Methods

The population included 1,034 African American (AA) survivors who received chemotherapy for breast, colorectal, lung or prostate cancer. CIPN prevalence was based on initial occurrence of worsening of self-reported pain, numbness or tingling after chemotherapy. Current CIPN included symptoms still present at the time of the survey, and persistent CIPN symptoms were present 12 or more months post-chemotherapy. CIPN severity was ranked as mild, moderate or severe. Logistic regression was utilized to evaluate sociodemographic and clinical factors associated with the various categories of CIPN.

Results

CIPN prevalence was 68%, with 53% current and 52% persistent. The symptom severity distribution based on prevalent CIPN included 32.2% mild, 30.8% moderate, and 36.9% severe. Factors associated with prevalent CIPN (odds ratio, 95% confidence interval) included primary cancer site (breast: 3.88, 2.02-7.46); and (colorectal: 5.37, 2.69-10.73), lower risk for older age at diagnosis (0.66, 0.53-0.83) and divorced/separated marital status (2.13, 1.42-3.21). Current CIPN was in addition, associated with more advanced stage disease trend (1.34, 1.08-1.66) and greater number of co-morbid medical conditions trend (1.23, 1.09-1.40), as was persistent CIPN. Severity of prevalent CIPN was associated with history of arthritis (1.55, 1.06-2.26) and severity of persistent CIPN with higher BMI (1.58, 1.07-2.35).

Conclusions

CIPN is a common and persistent complication in AA cancer survivors. Further research is needed to improve our understanding of CIPN predictors in all groups of cancer survivors.

SUBMITTER: Sreeram K 

PROVIDER: S-EPMC10373434 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Chemotherapy-induced peripheral neuropathy in the detroit research on cancer survivors (ROCS) cohort.

Sreeram Kalyan K   Seaton Randell R   Greenwald Mark K MK   Kamgar Mandana M   Assad Hadeel H   Baird Tara T   Schwartz Ann G AG   Ruterbusch Julie J   Simon Michael S MS  

Cancer causes & control : CCC 20230319 5


<h4>Purpose</h4>Improved life expectancy has increased the likelihood for long-term complications from chemotherapy among cancer survivors. One burdensome complication is chemotherapy-induced peripheral neuropathy (CIPN). We evaluated rates of CIPN outcomes in the Detroit Research on Cancer Survivorship (ROCS) cohort.<h4>Methods</h4>The population included 1,034 African American (AA) survivors who received chemotherapy for breast, colorectal, lung or prostate cancer. CIPN prevalence was based on  ...[more]

Similar Datasets

| S-EPMC8328798 | biostudies-literature
| S-EPMC5496793 | biostudies-literature
| S-EPMC6449184 | biostudies-literature
| S-EPMC9310052 | biostudies-literature
| S-EPMC8366077 | biostudies-literature
| S-EPMC7160396 | biostudies-literature
| S-EPMC8599933 | biostudies-literature
| S-EPMC8607253 | biostudies-literature
| S-EPMC5509538 | biostudies-literature
| PRJNA902082 | ENA